Liposarcoma – Pipeline Review, 2019

Liposarcoma is a type of soft tissue sarcoma, which usually begins with fat cells. Most commonly, liposarcoma occurs in the abdomen and in the muscles of the limb. Approximately 5,000 patients in the U.S. are affected with soft tissue sarcomas per year. Liposarcoma accounts for less than 20% of all soft tissue sarcomas and it has an annual incidence of 2.5 cases per million populations globally. A growing lump of tissue under the skin, pain, swelling, weakness of the affected limb, etc. are the symptoms of the liposarcoma in arms and legs. Moreover, liposarcoma in abdomen shows symptoms like abdominal swelling, abdominal pain, constipation, blood in stool, etc.

Diagnosis of liposarcoma can be done using imaging tests and other laboratory tests. Current treatment options available for liposarcoma include surgery, radiation therapy, and chemotherapy. Surgery is the main curative treatment, while patients with large high-grade liposarcomas can be treated with multimodality treatment with chemotherapy and radiation.

Academic research institutes and research laboratories have focused on studying and developing new treatment options for the liposarcoma. For instance; HDM201, which is being studied by Novartis, is currently in phase-1 clinical trials for the study of safety and efficacy of HDM201 in combination with LEE011 in patients with liposarcoma.

To know how our report can help streamline your business, Speak to Analyst

At present more than 50% of the pipeline candidates for liposarcoma are in the phase 2 stage. Majority of the studies have been sponsored by universities and research institutes. 

Report Description

The report on ‘Liposarcoma – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Liposarcoma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Liposarcoma.

The report on ‘Liposarcoma – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Liposarcoma
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Liposarcoma
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary